{"id":"W4309048303","doi":"10.1097/ppo.0000000000000635","title":"Antibody-Drug Conjugates in Myeloid Leukemias","year":2022,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Antibody-drug conjugate; Medicine; Calicheamicin; Monoclonal antibody; Cancer research; Targeted therapy; Leukemia; Cytotoxic T cell; Drug; Antibody; Immunology; Cancer; Oncology; Pharmacology; CD33; Internal medicine; Stem cell; Biology; In vitro","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003790724,0.0005164162,0.0008119429,0.001937932,0.0001837336,0.0006848341,0.0003918617,0.0008061174,0.00357521],"category_scores_gemma":[0.0004667288,0.0001790008,0.0003712766,0.001607063,0.0002772178,0.000782954,0.0004669618,0.001273336,0.001949045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004137081,"about_ca_system_score_gemma":0.000572315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006819002,"about_ca_topic_score_gemma":0.001049714,"domain_scores_codex":[0.9998311,0.00003357783,0.00002017049,0.00002576339,0.00007358102,0.00001588378],"domain_scores_gemma":[0.9998703,0.0000535771,0.00002237809,0.000004090195,0.00003670446,0.00001291447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008053247,0.00007356815,0.0001400036,0.01501245,0.0000713289,0.000200883,0.00004934513,0.0002832822,0.004141072,0.004216108,0.02159539,0.954136],"study_design_scores_gemma":[0.00002213093,0.0001002204,0.0003703736,0.001605615,0.00005900125,0.001033585,0.00002062423,0.00005351533,0.001289138,0.0007567834,0.9946797,0.00000913333],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000207211,0.9982122,0.00009321091,0.0001253332,0.000186943,0.000007336705,0.00001232312,0.000004869675,0.001150571],"genre_scores_gemma":[0.001723745,0.9964683,0.0001779233,0.0002182626,0.0001276999,0.000008461195,0.00003758206,0.000001530484,0.001236509],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00357521,"threshold_uncertainty_score":0.01196027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1013060180836298,"score_gpt":0.4469558710984948,"score_spread":0.345649853014865,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}